Protocol Ledger

NCT06375005 · Phase II · RECRUITING

Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

Interventional Phase II clinical trial protocol NCT06375005 sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-06 Enrollment: 38 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06375005
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)38 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06375005
Protocol FieldVerified Registry Value
NCT IdentifierNCT06375005
Consolidated Lead SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment38 participants (ESTIMATED)
Registered Start Date2025-01-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI